Pharmaceuticals, Biotechnology and Life Sciences
LONDON–(BUSINESS WIRE)–EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce that it has formed a…
ObsEva has completed recruiting patients for its Phase 3 clinical trial PRIMROSE 1 testing of oral gonadotropin releasing hormone (GnRH) receptor antagonist linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF).
4D pharma has started with a multicentre Phase I/II double-blind, placebo-controlled study of MRx-4DP0004 in patients with poorly controlled asthma.
Astrazeneca has entered partnership with the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) named the Lung Ambition Alliance, to try to eliminate lung cancer as a cause of death.
The U.S. FDA has granted accelerated approval to Karyopharm Therapeutics’s Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of certain adult patients with relapsed refractory multiple myeloma (RRMM).
Swedish Cyxone has submitted an application to the CEC in Poland for permission to start a clinical phase IIb trial with Cyxone’s drug candidate Rabeximod in RA , marking the first regulatory step towards the initiation of the study.
Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint) –
Tilray expands European leadership team
The award-winner of the 2019 Hansen Family Award is Professor Edith Heard. The Board of Trustees of the Bayer Science & Education Foundation and the Scientific Committee for this award have presented her with one of Germany’s most prestigious scientific accolades including a prize money of EUR 75,000.
OSS, Netherlands–(BUSINESS WIRE)–http://www.citryll.com/ announced today the first closing of a targeted € 15 million investment round, funded by ModiQuest B.V.,…